603718 Share Price Performance
Recent 603718 News & Updates
No updates
Shanghai Hile Bio-Technology Co., Ltd. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 28, 2025
- Earnings per share (EPS)
- 0.28
- Gross Margin
- 67.36%
- Net Profit Margin
- 70.77%
- Debt/Equity Ratio
- 0%
Shanghai Hile Bio-Technology Co., Ltd. Competitors
About 603718
- Founded
- 1981
- Employees
- 366
- CEO
- WebsiteView website
Shanghai Hile Bio-Technology Co., Ltd. researches, develops, produces, and sells veterinary biological products for livestock and poultry in China. The company offers swine fever live vaccines; trivalent inactivated vaccines for piglets; and inactivated vaccine for streptococcus suis. It also provides inactivated avian infectious rhinitis vaccines; newcastle disease and avian influenza combined inactivated vaccines; newcastle disease, infectious bronchitis, egg drop syndrome, and avian influenza quadruple inactivated vaccines; avian influenza inactivated vaccines; newcastle disease, infectious bronchitis, and avian influenza triple inactivated vaccines; avian infectious bronchitis live vaccines; avian newcastle disease, and avian infectious bronchitis combined live vaccines. The company was founded in 1981 and is based in Shanghai, China.
Chinese Market Performance
- 7 Days: 1.5%
- 3 Months: 13.1%
- 1 Year: 34.5%
- Year to Date: 13.5%
The market has climbed 1.5% in the last 7 days, lead by the Information Technology sector with a gain of 4.6%. In the last year, the market has climbed 35%. As for the next few years, earnings are expected to grow by 24% per annum. Market details ›
Companies across the globe are beginning to pay attention to agentic AI. It’s also a term you’re likely to hear a lot during earnings season. In fact, it came up 26 times during...
Continue reading